Abiomed
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Abiomed sits in the top decile of US sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count).
Abiomed: 20 sponsored US clinical trials, 2 recruiting.
Abiomed sponsors 20 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 8 completed. 2 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Coronary Artery Disease, with 2 trials.
Top-decile sponsor footprint
Abiomed ranks in the top decile of sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
8 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
20 total, page 1 of 1
Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
NCT06964685
Impella RP Flex with Smart Assist
NCT06637644
IMpella-Protected cArdiaC Surgery Trial (IMPACT)
NCT05529654
Use of the Impella BTR™ in Patients With Heart Failure: An Early Feasibility Study
NCT05291884
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
NCT04763200
The Smart Pump Study
NCT04465201
Impella ECP Early Feasibility Study
NCT04477603
Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial
NCT03947619
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
NCT06965504
The RECOVER IV Trial
NCT05506449
Impella Real-World Surveillance of Patients Using Sodium Bicarbonate
NCT05820451
Breethe Abiomed Recovery RegisTry (BART)
NCT05473130
SURPASS Impella 5.5 Study
NCT05100836
Restore EF Observational Study
NCT04648306
SVC Occlusion in Subjects With Acute Decompensated Heart Failure
NCT03836079
Door To Unloading With IMPELLA CP System in Acute Myocardial Infarction - Safety and Feasibility Study
NCT03000270
Trial Using Impella LP 2.5 System in Patients With Acute Myocardial Infarction Induced Hemodynamic Instability
NCT00972270
Protect II, A Prospective, Multicenter Randomized Controlled Trial
NCT00562016
RECOVER I Impella RECOVER LP/LD 5.0 Support System Safety and Feasibility Study
NCT00596726
PROTECT I, A Prospective Feasibility Trial Investigating the Use of IMPELLA RECOVER LP 2.5 System in Patients Undergoing High Risk PCI
NCT00534859
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 2 |
Therapeutic Areas
What is open in the Abiomed pipeline
2 recruiting of 20 indexed (10% open); 8 completed (40%).
Phase mix: 2 late (III/IV) vs 2 early (I/II) (balanced across stages).
Top condition: Coronary Artery Disease (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Abiomed: open-pipeline peers nationwide
Peers matched on 20 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Abiomed sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 20 trials (± recruiting share)
- 59th Medical Wing · 20 trials · 15% recruiting
- Agency for Healthcare Research and Quality (AHRQ) · 20 trials · 0% recruiting
- Alliance Foundation Trials · 20 trials · 15% recruiting
- Applied Science & Performance Institute · 20 trials · 0% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Aimmune Therapeutics · 10% recruiting · 10 trials
- Altria Client Services · 10% recruiting · 10 trials
- Alzheimer's Disease Cooperative Study (ADCS) · 10% recruiting · 10 trials
- Ascension Health · 10% recruiting · 10 trials
Related
What to do with this Abiomed page
20 registered trials is a research-attention snapshot, not an endorsement of Abiomed or any single study.
- 2 of Abiomed's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Coronary Artery Disease is the condition Abiomed studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Coronary Artery Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Abiomed pipeline card: 20 registered trials from official public datasets.Report a data error.